SCM Lifescience Co. Ltd
SCM Lifescience Co., Ltd. operates as a stem cell therapy company in South Korea. It develops SCM-AGH, a treatment for moderate to severe acute pancreatitis and moderate to severe atopic dermatitis, as well as chronic graft versus host disease; and Iroro Deerscalp, a toothbrush cosmetic for hair loss relief. The company was founded in 2014 and is headquartered in Incheon, South Korea.
Market Cap & Net Worth: SCM Lifescience Co. Ltd (298060)
SCM Lifescience Co. Ltd (KQ:298060) has a market capitalization of $17.29 Million (₩25.32 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #33318 globally and #2119 in its home market, demonstrating a -6.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SCM Lifescience Co. Ltd's stock price ₩773.00 by its total outstanding shares 32750281 (32.75 Million).
SCM Lifescience Co. Ltd Market Cap History: 2020 to 2026
SCM Lifescience Co. Ltd's market capitalization history from 2020 to 2026. Data shows change from $816.92 Million to $17.29 Million (-45.99% CAGR).
Index Memberships
SCM Lifescience Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.00% | #1175 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.00% | #1175 of 1384 |
Weight: SCM Lifescience Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
SCM Lifescience Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SCM Lifescience Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
SCM Lifescience Co. Ltd's market cap is 0.05 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $816.92 Million | $320.01 Million | -$9.63 Billion | 2.55x | N/A |
| 2021 | $321.97 Million | $439.26 Million | -$22.52 Billion | 0.73x | N/A |
| 2022 | $239.20 Million | $395.98 Million | -$22.93 Billion | 0.60x | N/A |
| 2023 | $84.55 Million | $695.70 Million | -$23.96 Billion | 0.12x | N/A |
| 2024 | $42.30 Million | $824.80 Million | -$12.38 Billion | 0.05x | N/A |
Competitor Companies of 298060 by Market Capitalization
Companies near SCM Lifescience Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to SCM Lifescience Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
SCM Lifescience Co. Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, SCM Lifescience Co. Ltd's market cap moved from $816.92 Million to $ 17.29 Million, with a yearly change of -45.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩17.29 Million | -23.62% |
| 2025 | ₩22.64 Million | -46.48% |
| 2024 | ₩42.30 Million | -49.97% |
| 2023 | ₩84.55 Million | -64.65% |
| 2022 | ₩239.20 Million | -25.71% |
| 2021 | ₩321.97 Million | -60.59% |
| 2020 | ₩816.92 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of SCM Lifescience Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.29 Million USD |
| MoneyControl | $17.29 Million USD |
| MarketWatch | $17.29 Million USD |
| marketcap.company | $17.29 Million USD |
| Reuters | $17.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.